Emergent Biosolutions Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on February 21, 2017, covering events occurring on February 14, 2017. The filing details actions taken by the Compensation Committee of the Board of Directors regarding the compensation of named executive officers, including 2016 cash bonuses, 2017 base salaries, and equity awards.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation figures.
Material Changes and Compensation Details
The Compensation Committee approved the following compensation adjustments:
- 2016 Cash Bonuses:
- Daniel J. Abdun-Nabi (CEO): $456,587.76
- Robert G. Kramer (CFO): $205,156.22
- Adam R. Havey (EVP, Biodefense): $149,611.28
- Fuad El-Hibri (Executive Chairman): Not bonus eligible
- 2017 Base Salaries and Target Bonuses (Effective Jan 1, 2017):
- Fuad El-Hibri: $993,532.80 salary; 0% target bonus
- Daniel J. Abdun-Nabi: $790,400.00 salary; 85% target bonus
- Robert G. Kramer: $503,131.20 salary; 60% target bonus
- Adam R. Havey: $440,294.40 salary; 50% target bonus
- Equity Awards (To be granted Feb 28, 2017):
- Performance-Based Stock Units (PSUs): Vesting is tied to net income as a percentage of total revenue for the 2019 fiscal year. Payout ranges from 50% to 150% of target shares based on performance.
- Total Award Values:
- Fuad El-Hibri: $1,800,000 (50% stock options, 50% time-based RSUs)
- Daniel J. Abdun-Nabi: $2,400,000 (50% stock options, 25% time-based RSUs, 25% PSUs)
- Robert G. Kramer: $1,000,000 (50% stock options, 25% time-based RSUs, 25% PSUs)
- Adam R. Havey: $525,000 (50% stock options, 25% time-based RSUs, 25% PSUs)
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk noted is the dilution of shareholder equity resulting from the issuance of stock options and restricted stock units, contingent upon the achievement of specific 2019 performance metrics.
Key Facts for Investor Verification
- Verify the specific performance metrics for the 2019 fiscal year required to vest the Performance-Based Stock Units.
- Confirm the total number of shares underlying the equity awards granted on February 28, 2017, based on the stated cash values and the stock price at the time of grant.
- Review the company's 2019 financial results to determine the actual payout percentage for the PSUs.
- Assess the impact of these compensation costs on the company's future earnings per share.